HEPION PHARMACEUTICALS, INC. Operating Expenses
HEPION PHARMACEUTICALS, INC. (HEPA) reported Operating Expenses of $1.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- HEPION PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-06-30 was $1.21M, a 30.59% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-03-31 was $798.51K, a 37.65% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-12-31 was $609.68K, a 49.28% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-09-30 was $527.90K, a 88.16% decline year-over-year.
- HEPION PHARMACEUTICALS, INC. operating expenses for fiscal 2025 was $4.16M, a 78.48% decline from fiscal 2024.
- HEPION PHARMACEUTICALS, INC. operating expenses for fiscal 2024 was $19.35M, a 60.07% decline from fiscal 2023.
- HEPION PHARMACEUTICALS, INC. operating expenses for fiscal 2023 was $48.45M, a 6.51% increase from fiscal 2022.
- HEPION PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $45.49M, a 49.62% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.21M 10-Q · filed 2026-08-13 | $2.01M 10-Q · filed 2026-08-13 | $2.62M derived: sum of 3 quarters · filed 2026-08-13 | $3.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $798.51K 10-Q · filed 2026-05-14 | $1.41M derived: sum of 2 quarters · filed 2026-05-14 | $1.94M derived: sum of 3 quarters · filed 2026-05-14 | $3.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $609.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.14M derived: sum of 2 quarters · filed 2026-03-12 | $2.88M derived: sum of 3 quarters · filed 2026-08-13 | $4.16M 10-K · filed 2026-03-12 |
| 2025-09-30 | $527.90K 10-Q · filed 2025-11-12 | $2.27M derived: sum of 2 quarters · filed 2026-08-13 | $3.55M 10-Q · filed 2025-11-12 | $4.76M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.75M 10-Q · filed 2026-08-13 | $3.03M 10-Q · filed 2026-08-13 | $4.23M derived: sum of 3 quarters · filed 2026-08-13 | $8.69M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.28M 10-Q · filed 2026-05-14 | $2.48M derived: sum of 2 quarters · filed 2026-05-14 | $6.94M derived: sum of 3 quarters · filed 2026-05-14 | $15.44M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.66M derived: sum of 2 quarters · filed 2026-03-12 | $14.16M derived: sum of 3 quarters · filed 2026-03-12 | $19.35M 10-K · filed 2026-03-12 |
| 2024-09-30 | $4.46M 10-Q · filed 2025-11-12 | $12.96M derived: sum of 2 quarters · filed 2025-11-12 | $18.14M 10-Q · filed 2025-11-12 | $28.55M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $8.50M 10-Q · filed 2025-08-14 | $13.69M 10-Q · filed 2025-08-14 | $24.09M derived: sum of 3 quarters · filed 2025-08-14 | $34.76M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $5.18M 10-Q · filed 2025-05-19 | $15.59M derived: sum of 2 quarters · filed 2025-05-19 | $26.26M derived: sum of 3 quarters · filed 2025-05-19 | $40.42M derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | $10.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08 | $21.07M derived: sum of 2 quarters · filed 2025-04-08 | $35.24M derived: sum of 3 quarters · filed 2025-04-08 | $48.45M 10-K · filed 2025-04-08 |
| 2023-09-30 | $10.66M 10-Q · filed 2024-11-14 | $24.83M derived: sum of 2 quarters · filed 2024-11-14 | $38.04M 10-Q · filed 2024-11-14 | $47.81M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $14.17M 10-Q · filed 2024-08-13 | $27.37M 10-Q · filed 2024-08-13 | $37.15M derived: sum of 3 quarters · filed 2024-08-13 | $45.61M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $13.21M 10-Q · filed 2024-05-21 | $22.98M derived: sum of 2 quarters · filed 2024-05-21 | $31.45M derived: sum of 3 quarters · filed 2024-05-21 | $51.45M derived: sum of 4 quarters · filed 2024-05-21 |
| 2022-12-31 | $9.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $18.24M derived: sum of 2 quarters · filed 2024-04-16 | $38.24M derived: sum of 3 quarters · filed 2024-04-16 | $45.49M 10-K · filed 2024-04-16 |
| 2022-09-30 | $8.47M 10-Q · filed 2023-11-20 | $28.46M derived: sum of 2 quarters · filed 2023-11-20 | $35.72M 10-Q · filed 2023-11-20 | $44.72M derived: sum of 4 quarters · filed 2023-11-20 |
| 2022-06-30 | $20.00M 10-Q · filed 2023-08-14 | $27.25M 10-Q · filed 2023-08-14 | $36.25M derived: sum of 3 quarters · filed 2023-08-14 | $44.77M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $7.25M 10-Q · filed 2023-05-12 | $16.25M derived: sum of 2 quarters · filed 2023-05-12 | $24.77M derived: sum of 3 quarters · filed 2023-05-12 | $31.62M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10 | $17.52M derived: sum of 2 quarters · filed 2023-04-10 | $24.37M derived: sum of 3 quarters · filed 2023-04-10 | $30.40M 10-K · filed 2023-04-10 |
| 2021-09-30 | $8.52M 10-Q · filed 2022-11-14 | $15.37M derived: sum of 2 quarters · filed 2022-11-14 | $21.40M 10-Q · filed 2022-11-14 | $26.36M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $6.85M 10-Q · filed 2022-08-15 | $12.89M 10-Q · filed 2022-08-15 | $17.84M derived: sum of 3 quarters · filed 2022-08-15 | $24.07M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $6.03M 10-Q · filed 2022-05-16 | $10.98M derived: sum of 2 quarters · filed 2022-05-16 | $17.22M derived: sum of 3 quarters · filed 2022-05-16 | $21.99M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | $11.18M derived: sum of 2 quarters · filed 2022-04-08 | $15.96M derived: sum of 3 quarters · filed 2022-04-08 | $20.15M 10-K · filed 2022-04-08 |
| 2020-09-30 | $6.23M 10-Q · filed 2021-11-15 | $11.01M derived: sum of 2 quarters · filed 2021-11-15 | $15.19M 10-Q · filed 2021-11-15 | $17.44M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $4.78M 10-Q · filed 2021-08-16 | $8.96M 10-Q · filed 2021-08-16 | $11.20M derived: sum of 3 quarters · filed 2021-08-16 | $13.12M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $4.19M 10-Q · filed 2021-05-14 | $6.43M derived: sum of 2 quarters · filed 2021-05-14 | $8.34M derived: sum of 3 quarters · filed 2021-05-14 | $10.04M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | $2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $4.15M derived: sum of 2 quarters · filed 2021-03-31 | $5.85M derived: sum of 3 quarters · filed 2021-03-31 | $7.77M 10-K · filed 2021-03-31 |
| 2019-09-30 | $1.91M 10-Q · filed 2020-11-16 | $3.61M derived: sum of 2 quarters · filed 2020-11-16 | $5.53M 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $1.70M 10-Q · filed 2020-08-12 | $3.62M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $1.92M 10-Q · filed 2020-06-29 | |||
| 2018-12-31 | $14.59M 10-K · filed 2020-05-14 | |||
| 2018-06-30 | $3.88M 10-Q · filed 2019-08-14 | $7.75M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $3.86M 10-Q · filed 2019-05-15 | |||
| 2017-12-31 | $10.52M 10-K · filed 2019-03-14 | |||
| 2017-06-30 | $21.02M 10-K · filed 2019-03-14 | |||
| 2017-03-31 | $4.91M 10-Q · filed 2018-05-15 | |||
| 2016-12-31 | $10.90M 10-KT · filed 2018-03-26 | |||
| 2016-06-30 | $20.81M 10-KT · filed 2018-03-26 | |||
| 2015-06-30 | $13.96M 10-K · filed 2016-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |